drug
methoxy polyethylene glycol-epoetin beta
Marketedupdated 6mo agoby Vifor Pharma Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying methoxy polyethylene glycol-epoetin beta
- phase3Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis
- phase3A Study of Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Predialysis Patients Not Treated With ESA.
- phase3A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
- —A Study of MIRCERA in Participants With Chronic Kidney Disease Stage 3-4 and Not on Dialysis
- phase3Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects
- phase2A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis
- phase3A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient
News(1)
- CSL pays $355M to co-develop Alentis’ phase 2-stage fibrosis drugAustralia’s CSL is paying $355 million upfront for the rights to Alentis Therapeutics’ phase 2-stage fibrosis drug.fiercebiotech · 27d ago
Data sources
last refreshed 37m ago
Found something off?
comments(0)
5-min edit window · permanent after that